Mon panier

Human GLP1R Protein, Fc Tag, low endotoxin (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
GLR-H5253-100ug
$395.00
GLR-H5253-1mg (500ug X 2)
$2500.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    GLP-1-R, GLP-1R, glucagon like peptide 1 receptor

  • Source

    Human GLP1R Protein, Fc Tag (GLR-H5253) is expressed from human 293 cells (HEK293). It contains AA Ala 21 - Glu 139 (Accession # P43220-1).

    Predicted N-terminus: Ala 21

    Request for sequence
  • Molecular Characterization

    GLP1R Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 40.2 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    GLP1R SDS-PAGE

    Human GLP1R Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    GLP1R SEC-MALS

    The purity of Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) is more than 85% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     GLP1R ELISA

    Immobilized Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) at 1 μg/mL (100 μL/well) can bind GLP-1R antibody with a linear range of 0.2-8 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     GLP1R SPR

    Anti-GLPR1 antibody immobilized on CM5 Chip can bind Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) with an affinity constant of 19.5 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  GLP1R SPR

    Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) immobilized on CM5 Chip can bind GLP-1 (7-37) with an affinity constant of 1.90 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     GLP1R BLI

    Loaded Human GLP1R Protein, Fc Tag (Cat. No. GLR-H5253) on Protein A Biosensor, can bind GLP-1 (7-37) with an affinity constant of 2.6 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

This gene encodes a 7-transmembrane protein that functions as a receptor for glucagon-like peptide 1 (GLP-1) hormone, which stimulates glucose-induced insulin secretion. This receptor, which functions at the cell surface, becomes internalized in response to GLP-1 and GLP-1 analogs, and it plays an important role in the signaling cascades leading to insulin secretion. It also displays neuroprotective effects in animal models. Polymorphisms in this gene are associated with diabetes. The protein is an important drug target for the treatment of type 2 diabetes and stroke.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Glucagon-like peptide-1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    13 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte